Source: ScreenPro Security
  • ScreenPro’s (SCRN) wholly-owned operating subsidiary Concierge Medical Consultants has launched Prestige Medical Care to private clientele in Vancouver
  • Prestige’s healthcare program delivers a full-service concierge health management system through personalized medical and non-medical care
  • ScreenPro is a screening and medical technology company that provides turnkey screening solutions with its proprietary medical alerting software
  • ScreenPro Security Inc. (SCRN) is trading steady at C$0.03 per share at 10:35 am ET

ScreenPro’s (SCRN) operating subsidiary Concierge Medical Consultants has launched Prestige Medical Care (PMC) to private clientele in Vancouver.

Prestige’s healthcare program delivers a full-service concierge health management system through personalized medical and non-medical care. It offers 24/7 medical care with house calls, virtual appointments, wellness visits, unlimited and same-day clinic visits, and prescriptions.

Lena Kozovski, Chief Executive Officer of Concierge, stated that with private health care on the rise as the public sector faces demand, this team of board-certified physicians and registered nurses are prepared to service the community.

“Management is confident that continued growth is expected for our medical division and look forward to expanding Concierge to help improve the lives of our community.”

The B.C. Medical Journal recently reported that 17.7 per cent of people in the province lacked a health care provider due to staff shortages.

ScreenPro is a screening and medical technology company that provides turnkey screening solutions with its proprietary medical alerting software.

ScreenPro Security Inc. (SCRN) is trading steady at C$0.03 per share at 10:35 am ET.

More From The Market Online

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.